Liu Zhengwang, Qiu Xiaotang, Yang Hua, Wu Xiaocui, Ye Wenjing, Zheng Xinbing
Department of Cardiovascular Medicine, Chinese Traditional Medicine Hospital of Hainan Province, Haikou, Hainan 570203, China.
Department of Endocrinology, Hainan Hospital of Traditional Chinese Medicine, Haikou, Hainan 570203, China.
Evid Based Complement Alternat Med. 2022 Nov 3;2022:4807175. doi: 10.1155/2022/4807175. eCollection 2022.
Based on a retrospective cohort study, to investigate the value of rivaroxaban combined with ticagrelor in antithrombotic therapy after PCI in patients with nonvalvular atrial fibrillation with acute coronary syndrome.
A total of 60 patients from January 2019 to May 2021 accepted therapy with antithrombotic therapy after PCI. The patients treated with ticagrelor were set as the control group, and those given rivaroxaban combined with ticagrelor were set as the research group. The curative effect, myocardial level, TIMI blood flow grade, platelet aggregation rate, and the incidence of cardiovascular events were taken from the comparisons.
The research group's therapeutic impact was superior to the control group's therapeutic impact, and the value was higher. After treatment, the myocardial levels of the two groups decreased, and the levels of troponin I, creatine kinase isoenzyme, and hypersensitive C-reactive protein in the research group were greatly less than those in the control group, and the difference was statistically significant ( < 0.05). After operation, the TIMI blood flow classification in the experimental group was better than that in the control group, and the difference was statistically significant ( < 0.05). The experimental group's platelet aggregation incidence was considerably lower than the control group's platelet aggregation incidence at 0.5 and 2 hours following surgery, and the difference was statistically significant ( < 0.05). The incidence of acute myocardial infarction, cardiogenic death, and intractable angina pectoris in the research group was significantly lower than that in the control group.
Rivaroxaban combined with ticagrelor in the treatment of nonvalvular atrial fibrillation with acute coronary syndrome after percutaneous coronary intervention; the TIMI blood flow grade is better than ticagrelor, which is of great significance to reduce mortality and has high safety in clinical application.
基于一项回顾性队列研究，探讨利伐沙班联合替格瑞洛在非瓣膜性心房颤动合并急性冠状动脉综合征患者经皮冠状动脉介入治疗（PCI）后抗血栓治疗中的价值。
选取2019年1月至2021年5月期间接受PCI后抗血栓治疗的60例患者。将接受替格瑞洛治疗的患者设为对照组，将给予利伐沙班联合替格瑞洛治疗的患者设为研究组。比较两组的疗效、心肌水平、心肌梗死溶栓治疗（TIMI）血流分级、血小板聚集率及心血管事件发生率。
研究组的治疗效果优于对照组，数值更高。治疗后，两组的心肌水平均下降，且研究组的肌钙蛋白I、肌酸激酶同工酶及超敏C反应蛋白水平均显著低于对照组，差异有统计学意义（<0.05）。术后，试验组的TIMI血流分级优于对照组，差异有统计学意义（<0.05）。术后0.5小时及2小时，试验组的血小板聚集发生率显著低于对照组，差异有统计学意义（<0.05）。研究组的急性心肌梗死、心源性死亡及难治性心绞痛发生率显著低于对照组。
利伐沙班联合替格瑞洛用于治疗经皮冠状动脉介入术后非瓣膜性心房颤动合并急性冠状动脉综合征；TIMI血流分级优于替格瑞洛，对降低死亡率具有重要意义，临床应用安全性高。
